NCT00049686View on ClinicalTrials.gov

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2002

Study Completion Date

January 31, 2008

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

laromustine

Trial Locations (1)

77030-4095

University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00049686 - VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter